Company Overview and News

1
Karyopharm Initiates NDA Submission Process for Selinexor

6h zacks
Karyopharm Therapeutics Inc. (KPTI - Free Report) announced that the company has initiated a rolling submission of a New Drug Application (NDA) to the FDA with a request for accelerated approval for its oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor. The company is seeking approval of selinexor for the treatment of patients with penta-refractory multiple myeloma having received at least three prior lines of therapy.
ALXN KPTI ILMN

17
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

22h zacks
Johnson and Johnson (JNJ - Free Report) announced that the FDA has approved Symtuza, a darunavir-based once-daily single-tablet regimen, for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults. Each film-coated tablet of Symtuza contains 800 mg of darunavir, 150 mg of cobicistat, 200 mg of emtricitabine and 10 mg of tenofovir alafenamide.
JNJ GSK ILMN GSK

0
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

2018-07-18 zacks
Roche Holding AG (RHHBY - Free Report) announced that the FDA has granted breakthrough therapy designation to its immuno-oncology drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced hepatocellular carcinoma (HCC).
RHHVF EXEL VNDA RHHBY ILMN RHHBF

47
You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18)

2018-07-18 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, July 17.
GOOS WSM GILD NFLX ILMN W NDAQ VIRT CELG LULU URBN MCD BBBY

14
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

2018-07-18 zacks
A jury in St. Louis ordered Johnson & Johnson (JNJ - Free Report) to pay $4.69 billion in damages to 22 women and their families who claimed that the company’s baby powder contained asbestos, which caused them to develop ovarian cancer. The verdict is the largest J&J has faced to date over allegations that its talc-based products cause cancer. The damages comprised $550 million in compensatory damages and $4.
HD ALXN JNJ ILMN

14
J&J's (JNJ) Phase III Study for Invokana Halted Earlier

2018-07-17 zacks
Johnson & Johnson (JNJ - Free Report) announced that its phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana (canagliflozin) is being stopped early based on positive pre-specified efficacy data. The study was evaluating the efficacy and safety of Invokana versus placebo when used in addition to standard of care for patients with chronic kidney disease (CKD) and type II diabetes (T2D).
HD ALXN JNJ ILMN

14
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

2018-07-17 zacks
A jury in St. Louis ordered Johnson & Johnson (JNJ - Free Report) to pay $4.69 billion in damages to 22 women and their families who claimed that the company’s baby powder contained asbestos, which caused them to develop ovarian cancer. The verdict is the largest J&J has faced to date over allegations that its talc-based products cause cancer. The damages comprised $550 million in compensatory damages and $4.
ALXN JNJ ILMN

63
Top Analyst Upgrades and Downgrades: Applied Materials, BioCryst, Costco, Generac, Goodyear, Intel, Microsoft, Netflix and More

2018-07-17 247wallst
Stocks were marginally lower on Tuesday after investors took a bite out of the FANG stocks. Investors have had less faith and lower rewards by buying the dips in 2018 than in prior years. Many of those investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for the longer term.
WFCNP LRCX PM DB AMT.PRB AMT.PRA MS.PRE WFC.PRL DRI MS.PRF NFLX WFC.PRJ MS.PRG NOMD ILMN MS.PRA KLAC CRL WFC.PRT SHW WFC.PRR WFC.PRQ WFC.PRP AMT WFC.PRO GNRC WFC.PRN AMAT WFC.PRY MS INTC WFC.PRX BLDR WFC.PRW WFC.PRV WFC WFC.WS COST BCRX MS.PRI MS.PRK ARW INNT TRI MSFT

19
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina

2018-07-16 zacks
Chicago, IL – July 16, 2018 - Stocks in this week’s article Lululemon Athletica Inc. (LULU - Free Report) , Sirius XM Holdings Inc. (SIRI - Free Report) , Nutrisystem, Inc. (NTRI - Free Report) and Illumina, Inc. (ILMN - Free Report) .
RM NTRI AMC ETM.WI ILMN FITBI ETM SIRI MTCH ROSEU GTT LULU FITB PAA NMM ROSE

8
4 Best Efficient Stocks to Add to Your Portfolio

2018-07-13 investorplace
Companies with favorable efficiency levels are likely to be on investors’ radar irrespective of market conditions. This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance.
SIRI NTRI LULU ILMN

8
4 Best Efficient Stocks to Add to Your Portfolio

2018-07-13 zacks
Companies with favorable efficiency levels are likely to be on investors’ radar irrespective of market conditions. This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance.
SIRI NTRI LULU ILMN

0
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

2018-07-12 zacks
Investors focused on the Medical space have likely heard of Illumina (ILMN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ILMN and the rest of the Medical group's stocks.
ILMN

0
BioTime (BTX) in Focus: Stock Moves 7.3% Higher

2018-07-12 zacks
BioTime, Inc. (BTX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.03 –$2.38 in the past one-month time frame, witnessed a sharp increase yesterday.
BTX ILMN

9
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump

2018-07-11 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
APTO APS ILMN

1
Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

2018-07-06 zacks
Chicago, IL – July 6, 2018 – Today, Zacks Equity Research discusses Computer - Storage Devices, including Amgen, Inc. (AMGN - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Illumina, Inc. (ILMN - Free Report) .
ANIP AMGN DB ELVT ILMN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ILMN / Illumina, Inc. on message board site Silicon Investor.

Illumina (ILMN) Optics for Genomics Illumina in position of capitalize on genetic tests at ferti
ILMN: Illumina, Inc.
CUSIP: 452327109